Your session is about to expire
← Back to Search
Device
BCT-HA Kit for Wrinkles
Phase < 1
Waitlist Available
Led By Maria Hordinsky, MD
Research Sponsored by University of Minnesota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 weeks after treatment 1st, 2nd and 3rd treatments and 32 weeks after enrollment
Summary
This trial will test a new skin treatment called Cellular MatrixTM BCT-HA Kit to see if it can make the midface look younger and healthier. It will also check for any safety issues.
Who is the study for?
This trial is for healthy men and women aged 30-65 with moderate to severe facial wrinkles, who can consent to study procedures and attend required visits. They must not have had aesthetic treatments in the past 6 months or plan any during the study. Exclusions include recent COVID vaccine recipients, allergy to hyaluronic acid, certain contraception non-users, pregnant/breastfeeding individuals, those with diabetes or immunosuppression, active skin infections/inflammations in the treatment area, severe bee allergies, recent dental procedures or HIV+/VHB+/VHC+.
What is being tested?
The trial tests Cellular MatrixTM BCT-HA Kit's effectiveness on midface rejuvenation versus PRP Only and a placebo. It focuses on safety and histological changes (skin tissue alterations) due to treatment. Participants will be randomly assigned to receive one of these interventions.
What are the potential side effects?
Potential side effects may include allergic reactions specific to hyaluronic acid components used in the kit such as redness or swelling at injection sites; however detailed side effect profiles will be monitored throughout the study.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 4 weeks after treatment 1st, 2nd and 3rd treatments and 32 weeks after enrollment
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 weeks after treatment 1st, 2nd and 3rd treatments and 32 weeks after enrollment
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in FACE-Q Score
Change in Global Aesthetic Improvement Scale
Change in Skin Quality Rating Scale
+3 moreTrial Design
3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: combined HA with PRPExperimental Treatment1 Intervention
Hyaluronic acid and PRP combination treatment
Group II: PRPActive Control1 Intervention
Platelet rich plasma without hyaluronic acid
Group III: PlaceboPlacebo Group1 Intervention
saline solution
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The Cellular MatrixTM BCT-HA Kit combines biological components and hyaluronic acid to rejuvenate the skin by enhancing hydration and stimulating collagen production. Hyaluronic acid, a naturally occurring substance in the skin, helps to retain moisture and add volume, thereby reducing the appearance of wrinkles.
Other common treatments include injectable soft tissue fillers, which provide immediate volume and support to the skin, and topical retinoic acid, which promotes cell turnover and collagen synthesis. These mechanisms are important for wrinkle patients as they address both the superficial and structural aspects of aging skin, leading to a more youthful and elastic appearance.
Topical retinoic acid treatment of photoaged skin: its effects on hyaluronan distribution in epidermis and on hyaluronan and retinoic acid in suction blister fluid.A novel, volumizing cosmetic formulation significantly improves the appearance of target Glabellar lines, nasolabial folds, and crow's feet in a double-blind, vehicle-controlled clinical trial.
Topical retinoic acid treatment of photoaged skin: its effects on hyaluronan distribution in epidermis and on hyaluronan and retinoic acid in suction blister fluid.A novel, volumizing cosmetic formulation significantly improves the appearance of target Glabellar lines, nasolabial folds, and crow's feet in a double-blind, vehicle-controlled clinical trial.
Who is running the clinical trial?
University of MinnesotaLead Sponsor
1,436 Previous Clinical Trials
1,621,618 Total Patients Enrolled
Maria Hordinsky, MDPrincipal InvestigatorUniversity of Minnesota
16 Previous Clinical Trials
354 Total Patients Enrolled
Media Library
Awards:
This trial has 0 awards, including: